Gene therapy shot aims to tame wet AMD
NCT ID NCT07053358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a single injection of LX111 gene therapy in 10 people aged 50 or older with wet age-related macular degeneration (nAMD). The goal is to see if it is safe and can help control the disease, possibly reducing the need for frequent eye injections. Participants must have already responded to standard anti-VEGF treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, 200080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection save vision in wet AMD?
- Eye injection aims to tame leading causes of blindness
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
- New eye drug aims to save sight in wet AMD
- Withdrawn study sought better way to time eye injections